Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 1:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 755 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Raised Intraocular Pressure Clear all

Conditions: Healthy, Glaucoma
Interventions: Not listed
Lead sponsor: Optovue; Industry
Eligibility: 18 Years and older
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Daly City, California

Conditions: Open Angle Glaucoma
Interventions: Combined cataract surgery with Hydrus microstent, Combined cataract surgery with iStent Inject W; Device
Lead sponsor: Diablo Eye Associates; Industry
Eligibility: 60 Years and older
Enrollment: 58 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Walnut Creek, California

Conditions: Primary Open-angle Glaucoma
Interventions: iStent inject, Cataract surgery; Device · Procedure
Lead sponsor: Glaukos Corporation; Industry
Eligibility: 45 Years and older
Enrollment: 505 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Racine, Wisconsin

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: High Dose Device, Low Dose Device, Placebo Device; Drug · Device
Lead sponsor: Vistakon Pharmaceuticals; Industry
Eligibility: 21 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 4
States / cities: Artesia, California • Louisville, Kentucky • Baltimore, Maryland + 1 more

Conditions: Primary Open Angle Glaucoma, Ocular Hypertension
Interventions: T-2345, Xalatan; Drug
Lead sponsor: Nephron Pharmaceuticals Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 335 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: El Paso, Texas

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: Brinzolamide 10 mg/ml + Timolol 5 mg/ml eye drops, suspension, Brinzolamide 10 mg/ml (AZOPT) eye drops, suspension, Timolol 5 mg/ml eye drops, solution; Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 523 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Glaucoma
Interventions: Not listed
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 40 Years to 79 Years
Enrollment: 832 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2015
U.S. locations: 5
States / cities: Los Angeles, California • Miami, Florida • Boston, Massachusetts + 2 more

Conditions: Normal Tension Glaucoma
Interventions: Not listed
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Primary Open Angle Glaucoma
Interventions: XEN63 Glaucoma Treatment System; Device
Lead sponsor: AbbVie; Industry
Eligibility: 45 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 29
States / cities: Glendale, Arizona • Culver City, California • Petaluma, California + 25 more

Conditions: Glaucoma, Glaucoma, Open Angle
Interventions: SOLX Titanium Sapphire Laser (TiSaLT), Argon Laser Trabeculoplasty (ALT); Device
Lead sponsor: SOLX, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 5
States / cities: Petaluma, California • Tampa, Florida • New York, New York + 2 more

Conditions: Glaucoma, Macular Degeneration, Glaucoma Suspect, Optic Neuropathy, Retinal Degeneration, Visual Pathway Disorder
Interventions: Visual Performance tests, Brain-computer interface; Diagnostic Test · Device
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 90 Years
Enrollment: 115 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Intraocular Pressure
Interventions: BOL-303259-X, Latanoprost; Drug
Lead sponsor: Bausch & Lomb Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 413 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Glaucoma, Suspect, Optic Nerve Hypoplasia and Abnormalities of the Central Nervous System, Congenital Coloboma of the Optic Nerve, Optic Nerve Head Pits, Bilateral Congenital
Interventions: Cartoon video fixation target and cartoon character voice audio instructions during Humphrey perimetry, Usual Care procedures during Humphrey perimetry for children; Device · Other
Lead sponsor: Nova Southeastern University; Other
Eligibility: 5 Years to 8 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2026
U.S. locations: 1
States / cities: Fort Lauderdale, Florida

Conditions: Glaucoma
Interventions: Ologen; Procedure
Lead sponsor: The New York Eye & Ear Infirmary; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Glaucoma, Glaucoma Following Surgery
Interventions: Digital microscope integrated with intraoperative OCT (Zeiss Artevo 800, Carl Zeiss Meditec AG), Spectralis Anterior-segment OCT (AS-OCT) (Heidelberg Engineering); Device
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Glaucoma and Ocular Hypertension
Interventions: Low Energy SLT, Standard Energy SLT; Procedure
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 790 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 28
States / cities: Laguna Hills, California • Pasadena, California • Sacramento, California + 22 more

Conditions: Open Angle Glaucoma
Interventions: Not listed
Lead sponsor: Massachusetts Eye and Ear Infirmary; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Open-angle Glaucoma, Ocular Hypertension
Interventions: AL-37807 Ophthalmic Suspension, 1.0%, Latanoprost, 0.005% (Xalatan), AL-37807 Vehicle, Timolol Maleate Ophthalmic Gel Forming Solution, 0.5%; Drug · Other
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: NCX 470 0.065% (initial phase of trial), Latanoprost 0.005% (initial phase of trial), NCX 470 0.1% (initial phase of trial), NCX 470 0.1% (remainder of trial), Latanoprost 0.005% (remainder of trial); Drug
Lead sponsor: Nicox Ophthalmics, Inc.; Industry
Eligibility: 18 Years to 84 Years
Enrollment: 691 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Glaucoma, Ocular Hypertension
Interventions: Netarsudil Ophthalmic Solution (Rhopressa), Artificial Tears (AT); Drug · Other
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Bloomington, Indiana

Conditions: Glaucoma
Interventions: Selective laser trabeculoplasty; Procedure
Lead sponsor: West Virginia University; Other
Eligibility: 30 Years and older
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Ocular Hypertension, Glaucoma
Interventions: Massage, Experimental insert, Sham insert; Device · Procedure
Lead sponsor: Temple University; Other
Eligibility: 30 Years to 90 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Glaucoma
Interventions: Not listed
Lead sponsor: Courtney Frazier Swaney; Other
Eligibility: 40 Years to 80 Years
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Glaucoma, Angle-closure, Primary, Acute
Interventions: QPI-1007 Injection, (including placebo); Drug
Lead sponsor: Quark Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 4
States / cities: Orange, California • Pasadena, California • Houston, Texas + 1 more

Search by objective public record fields.

Clinical Validation Study of RTVue Features

Combined Phacoemulsification With iStent Inject W Versus Hydrus for Mild to Moderate Open Angle Glaucoma

Multicenter Study Using Glaukos® Trabecular Micro-Bypass Stent Model GTS400 Using the G2-M-IS Injector System in Conjunction With Cataract Surgery

Safety and Efficacy of a Glaucoma Drug Delivery System

Safety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

A Study of a Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

Advanced Imaging for Glaucoma Study

IOP Lowering Effects of Topical Anesthetics Used Frequently in the Ophthalmology Clinic

A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma

SOLX Titanium Sapphire Laser for Trabeculoplasty

BCI and Evaluation of Visual and Task Performance in Subjects With Eye Diseases

Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Glaucoma or Ocular Hypertension

A More Engaging Visual Field Test to Increase Use and Reliability in Pediatrics

The Effectiveness of Ologen® Collagen Matrix in Preventing Intraocular Pressure (IOP) Spikes After Ahmed Glaucoma Valve Surgery (AGV-FP7)

Anterior-segment OCT (AS-OCT) and Intraoperative OCT (iOCT) for Trans- Conjunctival Needle Revision (TCNR)

Clarifying the Optimal Application of SLT Therapy Trial

Prevalence of Dyschromatopsia in Glaucoma Patients

A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension

Phase 3 Trial of NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Imaging the Effects of Netarsudil (Rhopressa) on the Trabecular Meshwork in Glaucoma and Ocular Hypertension

Glaucoma Management in the African-Derived Developing World Using Trabeculoplasty

Foot Reflexology in Ocular Hypertensive and Glaucoma Patients

Polarization Sensitive Retinal Tomography for Glaucoma Diagnosis

Phase IIA Double-Masked Randomized Sham-Controlled Trial of QPI-1007 Delivered by a Single Intravitreal Injection to Subjects With Acute Primary Angle-Closure Glaucoma (APACG)